KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Laguerre, Brigitte
Arija, Jose Angel Arranz
Oudard, Stephane
Fong, Peter C. C.
Kolinsky, Michael Paul
Augustin, Marinela
Feyerabend, Susan
Kam, Audrey E.
Gurney, Howard
Tafreshi, Ali
Retz, Margitta
Berry, William R.
Mar, Nataliya
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Catalan Inst Oncol, Barcelona, Spain
[3] CLCC Inst Paoli Calmettes, Paris, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Hosp Gregorio Maranon, Madrid, Spain
[6] Hop Europeen Georges Pompidou, Paris, France
[7] Auckland City Hosp, Auckland, New Zealand
[8] Cross Canc Inst, Edmonton, AB, Canada
[9] Paracelsus Med Univ, Nurnberg, Germany
[10] Studienpraxis Urol, Nurtingen, Germany
[11] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Univ Wollongong, Wollongong, NSW, Australia
[14] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[15] Duke Canc Ctr Cary, Cary, NC USA
[16] UCI Hlth, Orange, CA USA
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [2] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
    Augustin, Marinela
    Laguerre, Brigitte
    Baldini, Capucine
    Zedan, Ahmed H.
    Gonzalez-Billalabeitia, Enrique
    Fong, Peter C. C.
    Zukov, Ruslan
    Hammerer, Peter
    Prentice, Mark
    Shore, Neal D.
    Necchi, Andrea
    Todenhoefer, Tilman
    Kessler, Elizabeth R.
    Kose, Fatih
    Gurney, Howard
    Valderrama, Begona Perez
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
  • [5] Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
    Fong, Peter C. C.
    Kwiatkowski, Mariusz
    Mosca, Alessandra
    Valderrama, Begona Perez
    Huang, Yi-Hsiu
    Zedan, Ahmed H.
    Kuc, Kamil
    Wiechno, Pawel
    Laguerre, Brigitte
    Gonzalez-Billalabeitia, Enrique
    Osipov, Mikhail
    Dede, Didem Sener
    Goh, Jeffrey
    Daugaard, Gedske
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    Arija, Jose Angel Arranz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 149 - 149
  • [6] PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
    Nordquist, Luke T.
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhoefer, Tilman
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Massard, Christophe
    Stoeckle, Michael
    Carles, Joan
    Kolinsky, Michael Paul
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    de Bono, Johann S.
    JOURNAL OF UROLOGY, 2021, 206 : E417 - E417
  • [7] KEYNOTE-365 Cohort A: Pembrolizumab Plus Olaparib in Docetaxel-Pretreated Patients With Metastatic Castrate-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 14 - 15
  • [8] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P. C. C.
    Todenhoefer, T.
    Laguerre, B.
    Arranz Arija, J. A.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Kolinsky, M. P.
    Augustin, M.
    Gurney, H.
    Tafreshi, A.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
  • [9] Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony M.
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345